The American Society of Clinical Oncology (ASCO) is now seeking feedback regarding a clinical practice guideline protocol on HR-positive, non-HER2-overexpressing metastatic breast cancer. Individuals interested in providing their comments must agree to a confidentially agreement before they can view the guideline protocol Systemic Therapy and Biomarker Testing for HR-Positive, Non-HER2-Overexpressing Metastatic Breast Cancer: ASCO Living Guideline.
Click here to view the confidentiality agreement for the guideline protocol.
The public comment window is open through June 22, 2026, at 11:59 PM EST.